Yufen Zhong1, Zhongchen Zhang1, Yingying Lin1, Lili Wu2. 1. Department of Gastroenterology, The First People's Hospital of Wenling, Wenling, Zhejiang, China. 2. Taizhou Cancer Hospital, Wenzhou Medical University, Wenling, Zhejiang, China.
Abstract
BACKGROUND: Helicobacter pylori may have a protective effect against inflammatory bowel disease (IBD). We integrated epidemiological data to identify the correlation between IBD and H. pylori. Moreover, we analyzed whether IBD medication and classification affect H. pylori, and whether eradication of H. pylori leads to recurrence of IBD. METHODS: Articles published up to May 1, 2019, in three main databases including PubMed, MEDLINE and Embase, were searched. Study types included cross-sectional studies, retrospective studies and perspective studies, and data were combined and analyzed. Spearman correlation analysis and meta-analysis were performed after collecting and collating the relevant data. Sensitivity analysis and meta-regression were used to evaluate reliability and heterogeneity. RESULTS: Fifty-nine studies on IBD prevalence, 127 studies on H. pylori prevalence, and 23 studies for meta-analysis were included. IBD, ulcerative colitis (UC) and Crohn's disease (CD) were negatively correlated to H. pylori prevalence (all P<0.001). The meta-analysis results showed that compared to controls, the odds of having H. pylori infection were 0.44, 0.36, 0.54 for IBD, CD and UC, respectively (OR=0.44, 95% CI=0.34-0.59; OR=0.36, 95% CI=0.26-0.49; OR=0.54, 95% CI=0.4-0.72). Moreover, IBD patients were 1.41 times (OR=1.41, 95% CI=1.25-1.58) more likely to relapse after eradication of H. pylori. Finally, H. pylori infection was not related to IBD medication and classification. CONCLUSION: H. pylori prevalence was negatively correlated to IBD and H. pylori had a protective effect against IBD. Furthermore, eradication of H. pylori can lead to recurrence of IBD.
BACKGROUND: Helicobacter pylori may have a protective effect against inflammatory bowel disease (IBD). We integrated epidemiological data to identify the correlation between IBD and H. pylori. Moreover, we analyzed whether IBD medication and classification affect H. pylori, and whether eradication of H. pylori leads to recurrence of IBD. METHODS: Articles published up to May 1, 2019, in three main databases including PubMed, MEDLINE and Embase, were searched. Study types included cross-sectional studies, retrospective studies and perspective studies, and data were combined and analyzed. Spearman correlation analysis and meta-analysis were performed after collecting and collating the relevant data. Sensitivity analysis and meta-regression were used to evaluate reliability and heterogeneity. RESULTS: Fifty-nine studies on IBD prevalence, 127 studies on H. pylori prevalence, and 23 studies for meta-analysis were included. IBD, ulcerative colitis (UC) and Crohn's disease (CD) were negatively correlated to H. pylori prevalence (all P<0.001). The meta-analysis results showed that compared to controls, the odds of having H. pylori infection were 0.44, 0.36, 0.54 for IBD, CD and UC, respectively (OR=0.44, 95% CI=0.34-0.59; OR=0.36, 95% CI=0.26-0.49; OR=0.54, 95% CI=0.4-0.72). Moreover, IBD patients were 1.41 times (OR=1.41, 95% CI=1.25-1.58) more likely to relapse after eradication of H. pylori. Finally, H. pylori infection was not related to IBD medication and classification. CONCLUSION: H. pylori prevalence was negatively correlated to IBD and H. pylori had a protective effect against IBD. Furthermore, eradication of H. pylori can lead to recurrence of IBD.